Cabaletta Bio, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed March 21, 2024. Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune diseases. It operates as one reportable segment and has no approved products or product revenue.
Business Context and Development Status
- The company’s CABA platform includes CARTA, intended to broadly deplete CD19-positive B cells and potentially “reset” the immune system, and legacy CAART, intended to selectively eliminate disease-causing B cells.
- Lead candidate CABA-201 is being evaluated in Phase 1/2 RESET trials for systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis.
- DSG3-CAART is being evaluated in the Phase 1 DesCAARTes trial for mucosal pemphigus vulgaris, while MuSK-CAART is being evaluated in the Phase 1 MusCAARTes trial for MuSK-antibody-positive myasthenia gravis.
- RESET-SLE and RESET-Myositis were actively enrolling at year-end; the SSc and gMG programs had FDA-cleared INDs. The filing states that initial CABA-201 data were expected during 2024.
- Manufacturing depends substantially on Penn, CHOP, WuXi Advanced Therapies and other third-party suppliers. The company is pursuing additional CDMO capacity and potential manufacturing independence.
Financial Results and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $55.4 million | $39.3 million | +$16.1 million |
| General and administrative expense | $19.2 million | $14.8 million | +$4.4 million |
| Total operating expenses | $74.7 million | $54.1 million | +$20.5 million |
| Interest income | $7.0 million | $1.2 million | +$5.8 million |
| Net loss | $(67.7) million | $(53.0) million | Loss increased by $14.7 million |
| Net loss per share | $(1.65) | $(1.81) | Improved on increased share base |
| Cash used in operating activities | $(53.5) million | $(46.4) million | Greater cash burn |
| Cash, cash equivalents and short-term investments | $241.2 million | $106.5 million | +$134.7 million |
- Cash and cash equivalents were $193.2 million and short-term investments were $48.0 million at December 31, 2023.
- The company reported an accumulated deficit of $233.2 million and expects continued operating losses.
- The filing identifies no material debt financing. Total liabilities were $17.5 million, primarily accounts payable, accrued liabilities and operating lease liabilities.
- Operating cash burn increased primarily because of higher personnel, development, clinical trial and manufacturing costs. Stock-based compensation was $11.3 million in 2023 versus $6.9 million in 2022.
- Financing activities provided $187.6 million, including $93.8 million of net proceeds from the May 2023 public offering and $91.7 million of net proceeds from 2023 at-the-market sales.
- Management expects existing cash, cash equivalents and investments to fund operations into the first half of 2026, including initial clinical data; management cautions that the estimate is based on assumptions that may prove incorrect and that additional financing will be required.
Material Changes Versus 2022
- Research and development expense increased 41%, driven by higher personnel costs, clinical trial activity, development services and manufacturing costs; sponsored research expense declined after CAART-related agreements were completed in 2022.
- General and administrative expense increased 30%, primarily due to personnel, stock-based compensation, legal, information technology and other administrative costs.
- Clinical and regulatory activity expanded substantially: CABA-201 INDs were cleared for SLE, myositis, systemic sclerosis and gMG during 2023, and RESET-SLE and RESET-Myositis began enrolling.
- The company expanded its WuXi manufacturing relationship for CABA-201 and MuSK-CAART, expanded its Oxford Biomedica vector license and supply arrangements to include CABA-201, and began a proof-of-concept technology-transfer collaboration with Cellares.
- Shares outstanding increased from 29.4 million at December 31, 2022 to 47.8 million at December 31, 2023, primarily reflecting equity financings and warrant exercises.
Guidance, Outlook, Risks and Unusual Items
- Outlook: Management plans to advance CABA-201 across multiple autoimmune indications, file additional INDs, expand manufacturing capacity and continue clinical enrollment. No product-sales or profitability guidance was provided.
- Clinical risk: All programs remain early-stage, open-label and subject to enrollment delays, inconclusive efficacy, dose limitations, clinical holds and serious adverse events, including cytokine release syndrome, neurotoxicity, infections, prolonged B-cell depletion and hypogammaglobulinemia.
- Class-wide safety risk: The FDA was investigating T-cell malignancies associated with certain CD19- or BCMA-directed CAR-T therapies and required lifelong malignancy monitoring for CABA-201 trial participants. The filing states that the risk-benefit threshold may be more demanding in autoimmune diseases than in oncology.
- Manufacturing and supply risk: Product manufacture is patient-specific, complex and not yet validated for commercial-scale production. Dependence on Penn, WuXi, Oxford and other suppliers creates capacity, quality, technology-transfer and geopolitical risks.
- China-related risk: Proposed or future U.S. restrictions involving Chinese biotechnology suppliers could affect WuXi and the company’s clinical manufacturing plans.
- Funding and dilution: The company expects to require substantial additional capital. Future equity offerings may dilute existing stockholders, while debt or partnerships could impose restrictive terms or require relinquishing rights.
- Licensing obligations: The IASO license includes potential milestone payments of up to $162 million, plus royalties; Penn, Oxford and Autolus arrangements also include contingent milestones and royalties. A $1.5 million IASO milestone was paid in the first quarter of 2024 after the first CABA-201 patient was dosed.
- Unusual post-period items: The remaining $100 million 2023 ATM program was completed and terminated on March 21, 2024, generating approximately $5.7 million of additional net proceeds after year-end.
- The company reported no material legal proceedings as of December 31, 2023. Management concluded that disclosure controls and internal control over financial reporting were effective; no auditor attestation was required because the company remained an emerging growth company.
Investor Verification Checklist
- Verify enrollment, safety findings and efficacy signals from the RESET-SLE, RESET-Myositis, RESET-SSc and RESET-MG trials, including CRS, ICANS, infection and B-cell-recovery data.
- Confirm whether clinical timelines, cohort sizes, endpoints or regulatory plans have changed since the filing.
- Assess cash burn and updated liquidity after the first-quarter 2024 IASO milestone payment, completion of the ATM program and any subsequent financing.
- Review manufacturing readiness, capacity commitments, minimum-run obligations and contingency plans for Penn, WuXi, Oxford and Cellares.
- Monitor FDA actions concerning T-cell malignancies, lifelong monitoring requirements and any changes to the benefit-risk assessment for CAR-T therapies in autoimmune disease.
- Review potential dilution from outstanding options, the remaining 1.17 million pre-funded warrants at year-end, equity plans and future capital raises.
- Evaluate the scope and durability of the Penn and IASO intellectual-property licenses, including milestone, royalty, diligence and termination provisions.